BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Casi Pharmaceuticals, Inc. CASIF
6 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 20.7M
Revenue, FY2025 · full 6-year series below
Revenue $M
Net income $M
FY2025 · Revenue 20.7 · Net income -48.1
Compound annual growth
Revenue compounded at +6.5% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−232 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -217.3% · Net -232.0%
ROE
FY2024 · ROE -301.8%
The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 |
| Income tax $B | · | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −2.59 | −2.56 | −2.02 | −3.01 | −2.69 | −4.37 |
| Dividend / sh $ | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · |
| ROE % | · | −301.8 | −78.4 | −63.6 | −44.2 | −59.2 |
| Shares out B | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 28 reconciliationsAUDITED
Reconciled in 6 of 19 fiscal years. 67 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
Data on record since2020